Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting

r th I t L 1 The Proper th i Commercial business is performing well "We are all-in on immunology, across therapeutic areas." We are all-in on Immunology, across therapeutic areas Unprecedented pipeline of blockbuster opportunities Amlitelimab shows significant improvements in signs In addition to the healthy immunology pipeline, we should see business development transactions that should complement the product portfolio and pipeline. Management seems more focused on bolt-on deals in the range EUR2 billion t ...